文献速递自身免疫性与大疱性皮肤病湿疹皮炎与荨麻疹

显性营养不良型大疱性表皮松解症与糖酵解活跃的GATA3+ Th2细胞相关,可能参与皮损瘙痒

Dominant dystrophic epidermolysis bullosa is associated with glycolytically active GATA3+ T helper 2 cells which may contribute to pruritus in lesional skin.
PubMed 文献 · Br J Dermatol · 2024-01-01

本研究通过bulk RNA测序和单细胞转录组分析6例瘙痒型DDEB患者及4例健康对照皮肤,发现DDEB皮损中Th1/2和Th17通路显著富集,单细胞水平显示糖酵解活跃的GATA3+ Th2细胞与皮损相关。3例患者接受度普利尤单抗治疗12周后VAS瘙痒评分从均值7.83降至3.83,支持抗Th2药物用于DDEB瘙痒。

要点

  • DDEB皮损中Th1/2和Th17通路显著富集,单细胞水平见糖酵解活跃的GATA3+ Th2细胞。
  • 度普利尤单抗治疗12周后VAS瘙痒评分均值从7.83降至3.83。
  • 抗Th2药物可能为DDEB瘙痒提供药物重定位治疗选择。

核心结论

  • DDEB相关Th2免疫特征增强,为抗Th2药物重定位治疗DDEB瘙痒提供依据。

研究设计与样本

  • 对6例DDEB患者(均为瘙痒型)和4例健康对照的皮损与非皮损皮肤行bulk RNA测序。
  • 获取2例DDEB皮损、1例DDEB非皮损和2例健康皮肤的单细胞转录组。
  • 3例DDEB患者接受度普利尤单抗治疗。

主要发现

  • DDEB皮损较非皮损和健康皮肤显著富集Th1/2和Th17通路。
  • 单细胞转录组显示DDEB皮损中糖酵解活跃的GATA3+ Th2细胞相关。
  • 3例患者度普利尤单抗治疗12周后VAS瘙痒评分均值3.83,低于治疗前均值7.83。
  • 健康皮肤与度普利尤单抗治疗的EB瘙痒症皮肤转录组谱相似,Th1/Th2和Th17通路富集降低。

临床怎么用

  • 度普利尤单抗可能用于缓解DDEB瘙痒,但需临床试验验证。
  • 单细胞RNA测序有助于识别DDEB瘙痒的免疫靶点。

局限性

  • 样本量小(DDEB患者6例,单细胞分析例数更少)。
  • 度普利尤单抗治疗仅3例,缺乏对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dominant dystrophic epidermolysis bullosa (DDEB) is characterized by trauma-induced blisters and, in some individuals, intense pruritus. Precisely what causes itch in DDEB and optimal ways to reduce it have not been fully determined. OBJECTIVES: To characterize DDEB skin transcriptomes to identify therapeutic targets to reduce pruritus in patients. METHODS: Using bulk RNA sequencing, we evaluated affected and unaffected skin biopsy samples from six patients with DDEB (all with the very itchy pruriginosa subtype) and four healthy individuals. Single-cell transcriptomes of affected (n = 2) and unaffected (n = 1) DDEB skin and healthy skin (n = 2) were obtained. Dupilumab treatment was provided for three patients. RESULTS: The skin bulk transcriptome showed significant enrichment of T helper (Th)1/2 and Th17 pathways in affected DDEB skin compared with nonlesional DDEB skin and healthy skin. Single-cell transcriptomics showed an association of glycolytically active GATA3+ Th2 cells in affected DDEB skin. Treatment with dupilumab in three people with DDEB led to significantly reduced visual analogue scale (VAS) itch scores after 12 weeks (mean VAS 3.83) compared with pretreatment (mean VAS 7.83). Bulk RNAseq and quantitative polymerase chain reaction showed that healthy skin and dupilumab-treated epidermolysis bullosa (EB) pruriginosa skin have similar transcriptomic profiles and reduced Th1/Th2 and Th17 pathway enrichment. CONCLUSIONS: Single-cell RNAseq helps define an enhanced DDEB-associated Th2 profile and rationalizes drug repurposing of anti-Th2 drugs in treating DDEB pruritus. Dominant dystrophic epidermolysis bullosa (DDEB) is a rare inherited skin disease that causes fragile skin that blisters easily, often triggered by minor injuries. These blisters are accompanied by intense itching, which can be distressing. The underlying cause of DDEB lies in genetic mutations in a gene called COL7A1. This gene encodes ‘type VII collagen’, a protein crucial for attaching the outer skin layer (epidermis) to the layer beneath (dermis). Although the genetic basis of DDEB is understood, the causes of itch are not known. As well as this, effective treatments for DDEB are lacking, which has driven scientists to explore innovative approaches like repurposing existing drugs. Drug repurposing involves using medications that have already been approved for other health conditions. One such drug is dupilumab, which is used for severe atopic dermatitis (eczema). Dupilumab targets immune cells called Th2 cells, which play a role in inflammation and allergies. While dupilumab has shown promise in relieving DDEB itching, the way it works in this condition is unclear. This study, carried out by a group of researchers in Taiwan, looked at gene expression in DDEB-affected and unaffected skin, and compared it to gene expression in healthy skin samples. We found heightened activity in Th2 immune cells and abnormal gene signals related to itching, similar to atopic dermatitis. These findings support using dupilumab and other anti-inflammatory drugs to alleviate itching in DDEB. Clinical trials will be crucial to evaluate the effectiveness of these drugs for managing DDEB symptoms. This research opens doors for enhanced treatment options and improving the quality of life of people living with DDEB.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Aala WJF, Hou PC, Hong YK, et al. Dominant dystrophic epidermolysis bullosa is associated with glycolytically active GATA3+ T helper 2 cells which may contribute to pruritus in lesional skin. Br J Dermatol. 2024. PMID: 38477474. doi:10.1093/bjd/ljae110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。